1. Home
  2. MAIA vs GLU Comparison

MAIA vs GLU Comparison

Compare MAIA & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • GLU
  • Stock Information
  • Founded
  • MAIA 2018
  • GLU 2004
  • Country
  • MAIA United States
  • GLU United States
  • Employees
  • MAIA N/A
  • GLU N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • MAIA Health Care
  • GLU Finance
  • Exchange
  • MAIA Nasdaq
  • GLU Nasdaq
  • Market Cap
  • MAIA 46.7M
  • GLU 99.4M
  • IPO Year
  • MAIA 2022
  • GLU N/A
  • Fundamental
  • Price
  • MAIA $1.85
  • GLU $17.63
  • Analyst Decision
  • MAIA
  • GLU
  • Analyst Count
  • MAIA 0
  • GLU 0
  • Target Price
  • MAIA N/A
  • GLU N/A
  • AVG Volume (30 Days)
  • MAIA 543.2K
  • GLU 12.4K
  • Earning Date
  • MAIA 08-08-2025
  • GLU 01-01-0001
  • Dividend Yield
  • MAIA N/A
  • GLU 8.60%
  • EPS Growth
  • MAIA N/A
  • GLU N/A
  • EPS
  • MAIA N/A
  • GLU 0.62
  • Revenue
  • MAIA N/A
  • GLU N/A
  • Revenue This Year
  • MAIA N/A
  • GLU N/A
  • Revenue Next Year
  • MAIA N/A
  • GLU N/A
  • P/E Ratio
  • MAIA N/A
  • GLU $22.50
  • Revenue Growth
  • MAIA N/A
  • GLU N/A
  • 52 Week Low
  • MAIA $1.40
  • GLU $11.61
  • 52 Week High
  • MAIA $4.24
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 53.36
  • GLU 71.86
  • Support Level
  • MAIA $1.82
  • GLU $16.98
  • Resistance Level
  • MAIA $2.03
  • GLU $17.35
  • Average True Range (ATR)
  • MAIA 0.12
  • GLU 0.21
  • MACD
  • MAIA 0.02
  • GLU 0.06
  • Stochastic Oscillator
  • MAIA 58.14
  • GLU 93.64

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: